Is Adaptimmune Therapeutics a Buy?
Cancer is one of the most challenging conditions for investigational therapies to target because malignant cells are frequently able to disguise themselves as healthy cells, thereby surpassing detection from the body's immune system. One biotech company that's gaining ground in this field is Adaptimmune Therapeutics (NASDAQ: ADAP), which has a variety of pipeline candidates under investigation for targeting 10 types of solid tumors.
Even though it can be very risky to invest in small-cap cancer immunotherapy stocks, the company does have a few tricks up its sleeves to safeguard investors. Wall Street seems to agree, as institutional investors own 14% of the company. Without further ado, let's take a look at the potential perks and downfalls of investing in Adaptimmune.
Image Source: Getty Images
Source Fool.com